Compare Regeneron Pharmaceuticals Inc (REGN) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Wheaton Precious Metals Corp — how do they compare? Regeneron Pharmaceuticals Inc trades at $808.33 (market cap $83.15B), while Wheaton Precious Metals Corp trades at $154.96 (market cap $71.45B). The key difference: Regeneron Pharmaceuticals Inc is the larger of the two by market cap, and Wheaton Precious Metals Corp pays the higher dividend (0.5%). Which is the better fit depends on your goals.
| REGN | WPM | |
|---|---|---|
Market Cap | $83.15B | $71.45B |
Sector | Health | Basic Materials |
52-Week High | $852.03 | $165.72 |
52-Week Low | $555.51 | $94.37 |
Enterprise Value | $77.86B | $73.33B |
Dividend Yield | 0.47% | 0.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% on the day, with a bullish technical signal from moving averages and a neutral RSI near 54. The stock shows strong profitability with a net income margin of 27.86% and consistent earnings beats in recent quarters. However, multiple class-action lawsuits filed in September 2026 allege securities fraud related to a Phase 3 clinical trial disclosure, creating near-term uncertainty.
The outlook remains cautiously optimistic given robust fundamentals and a 69% analyst buy rating, but legal overhangs and a projected earnings dip in 2026 pose risks. Upside hinges on legal resolution and pipeline execution, while downside is capped by institutional support like CalSTRS' recent $79 billion position increase.
Wheaton Precious Metals (WPM) trades at $155.11, up 0.08% with a bullish technical outlook and strong institutional support. The company delivered three consecutive quarterly earnings beats, with Q2 2026 EPS of $1.19 beating expectations of $1.15. Revenue surged to $2.31 billion in 2025 with exceptional 64.66% net margins, while cash flow from operations reached $1.90 billion. Analysts maintain 80% buy ratings with a $161.75 consensus target, representing 4.3% upside potential.
WPM's streaming model provides leveraged exposure to precious metals without mining operational risks, supported by fully-funded growth pipeline targeting 50% production increase by 2030. Key risks include commodity price volatility and execution of the ambitious $5.1 billion 2026 investment plan. The stock offers growth potential but requires monitoring of gold/silver price trends and capital deployment efficiency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
